News

Cryoport Systems now supporting 7 commercial therapies globally

July 27, 2021

We're celebrating big news from two Cryoport Systems valued clients : bluebird bio an,d Bristoltherapy for patients with multiple myeloma. This also means Cryoport Systems is now supporting the distribution of seven commercial therapies gloablly;

-KYMRIAH (Novartis) Approved in the US, EU, Japan, and Singapore

-YESCARTA (Gilead Sciences) Approved in the US and EU

-Zynteglo (bluebird bio) Approved in the EU

-TECARTUS (Gilead Sciences) Approved in the US

-Libmedly (Orchard Therapeutics) Approved in the EU

-BREYANZI (Bristol Myers-Squibb) Approved in the US and Japan

-Abecma (bluebird bio and Bristol Myers-Squibb) Approved in the US

In addition tot the above therapies, Cryoport Systems is providing the supply chain support for 543 cell and gene therapy clinical trials across the globe. The company's acquisitions of CRYOPDP and MVE Biological Solutions in 2020 established a more robust and flexible global support network, enabling the company to reach more suppliers, trials and patients.

News

Landau Partnership

September 22, 2021

VectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a world leader in developing nonhuman primate (NHP) models for clinical research applications, have...

Learn more

Univercells Partnership

September 16, 2021

VectorBuilder – a global leader in vector design, optimization, and GMP manufacturing – has formed a worldwide strategic partnership with Univercells Technologies, a provider of novel biomanufacturing technologies for flexible...

Learn more

The MACSima™ Imaging Platform is the only complete solution for ultra high content imaging experiments.

September 13, 2021

Learn more

New automated process to simplify the manufacturing of gene-engineered hematopoietic stem cells with the CliniMACS Prodigy® HSC Engineering System

September 13, 2021

Learn more

MedXCell SA

August 25, 2021

MedXCell Science SA: MedXCell Science SA was co-founded in 2018 by the University Hospital of Montpellier (CHU of Montpellier) in France and the Swiss company MedXCell SA. It was the...

Learn more

Polyplus-transfection initiates construction of Vectura, a new 4,000m2 facility

July 23, 2021

Learn more

Polyplus-transfection® launches FectoVIR®-AAV

July 23, 2021

Learn more

RD-Biotech: a new company from Besançon wins the « France Relance » call for projects

February 22, 2021

Following the unprecedented health crisis and its unprecedented economic impact, the Government has put in place numerous tools to support businesses.

Learn more

Covi-TRaC: arming our immune cells against SARS-COV2

September 11, 2020

A prolific period for researchers, confinement has allowed the Etablissement Français du Sang teams to generate and mature many ideas from pre-existing research. In Besançon, Marina Deschamps and Christophe Ferrand...

Learn more